Ra Capital Management as of June 30, 2018
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 27 positions in its portfolio as reported in the June 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Wave Life Sciences (WVE) | 18.7 | $287M | 7.5M | 38.25 | |
| Ascendis Pharma A S (ASND) | 18.3 | $282M | 4.2M | 66.52 | |
| Solid Biosciences | 6.2 | $96M | 2.7M | 35.63 | |
| Endocyte | 5.1 | $78M | 5.6M | 13.80 | |
| Momenta Pharmaceuticals | 4.9 | $76M | 3.7M | 20.45 | |
| Immunomedics | 4.8 | $74M | 3.1M | 23.67 | |
| Myovant Sciences | 4.2 | $65M | 2.8M | 22.87 | |
| Inflarx Nv (IFRX) | 4.1 | $63M | 2.0M | 32.25 | |
| Tg Therapeutics (TGTX) | 3.6 | $56M | 4.3M | 13.15 | |
| Sage Therapeutics (SAGE) | 3.6 | $55M | 351k | 156.53 | |
| Zogenix | 3.3 | $51M | 1.1M | 44.20 | |
| Dicerna Pharmaceuticals | 3.1 | $48M | 3.9M | 12.25 | |
| Rhythm Pharmaceuticals (RYTM) | 3.1 | $48M | 1.5M | 31.26 | |
| Eidos Therapeutics | 2.9 | $44M | 2.2M | 20.34 | |
| BioCryst Pharmaceuticals (BCRX) | 2.6 | $40M | 7.0M | 5.73 | |
| Ra Pharmaceuticals | 2.5 | $38M | 3.9M | 9.95 | |
| Kala Pharmaceuticals | 1.9 | $29M | 2.1M | 13.73 | |
| Apellis Pharmaceuticals (APLS) | 1.3 | $20M | 900k | 22.00 | |
| Clearside Biomedical (CLSD) | 1.1 | $16M | 1.5M | 10.69 | |
| Scpharmaceuticals (SCPH) | 1.1 | $16M | 2.9M | 5.66 | |
| Iovance Biotherapeutics (IOVA) | 0.9 | $14M | 1.1M | 12.80 | |
| Kalvista Pharmaceuticals (KALV) | 0.8 | $12M | 1.4M | 8.12 | |
| AVEO Pharmaceuticals | 0.7 | $11M | 5.1M | 2.26 | |
| Spero Therapeutics (SPRO) | 0.7 | $11M | 742k | 14.67 | |
| Glycomimetics (GLYC) | 0.3 | $4.1M | 254k | 16.13 | |
| Proteon Therapeutics | 0.2 | $3.3M | 1.3M | 2.45 | |
| G1 Therapeutics (GTHX) | 0.1 | $1.7M | 40k | 43.45 |
